CYRXIndustrials · Integrated Freight & LogisticsThe 9 Wall Street analysts covering CryoPort, Inc. hold a median 12-month price target of $20 — +31.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 68 of 100 as at 15 Aug 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores CryoPort, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (97): The shares have been drifting up relative to others.
Growth (42): Sales and profits are flat, shrinking, or growing more slowly than they were.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on CYRX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +31.1% from it.
Of the 20 most recent actions, 4 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 7 Aug 2026 | Guggenheim | Maintains | Buy | $12 → $16 |
| 7 Aug 2026 | Needham | Maintains | Buy | $15 → $19 |
| 24 July 2026 | BTIG | Maintains | Buy | — |
| 24 July 2026 | BTIG | Maintains | Buy | $17 → $25 |
| 3 June 2026 | Craig-Hallum | Maintains | Buy | $15 → $20 |
| 3 June 2026 | Craig-Hallum | Maintains | Buy | — |
| 20 May 2026 | Keybanc | Maintains | Overweight | — |
| 5 May 2026 | BTIG | Maintains | Buy | — |
| 5 May 2026 | Guggenheim | Maintains | Buy | — |
| 5 May 2026 | Needham | Maintains | Buy | — |
| 30 Mar 2026 | Craig-Hallum | Initiates | Buy | — |
| 4 Mar 2026 | Needham | Maintains | Buy | — |
| 5 Nov 2025 | Needham | Maintains | Buy | — |
| 5 Nov 2025 | UBS | Maintains | Buy | — |
| 18 Sept 2025 | BTIG | Maintains | Buy | — |
| 6 Aug 2025 | Keybanc | Upgrade | Overweight | — |
| 6 Aug 2025 | Leerink Partners | Upgrade | Outperform | — |
| 22 July 2025 | Stephens & Co. | Assumes | Overweight | $13 |
| 7 July 2025 | BTIG | Maintains | Buy | — |
| 8 May 2025 | Needham | Reiterates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CYRX appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 58% of US stocks
Cheaper than 31% of US stocks
Cheaper than 51% of US stocks
Cheaper than 97% of US stocks
Higher than 46% of US stocks
Higher than 45% of US stocks
Higher than 58% of US stocks
Higher than 21% of US stocks
Higher than 16% of US stocks
Higher than 38% of US stocks
Higher than 36% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own CryoPort, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
CryoPort (CYRX) was upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about its earnings prospects, according to Zacks Investment Research.
Why it matters — The upgrade signals improved analyst sentiment around CryoPort's earnings outlook, which CYRX watchers would take note of.
Seeking Alpha published the Q2 2026 earnings call transcript for Cryoport, Inc. (CYRX), covering the company's second-quarter financial results and management commentary. The transcript was released as part of the company's quarterly earnings reporting.
Why it matters — The transcript provides CYRX watchers with direct access to management's discussion of the company's Q2 2026 performance and outlook.
CryoPort reported second-quarter 2026 revenue of $49 million and said it reached positive adjusted EBITDA from continuing operations. The company reaffirmed its full-year revenue outlook of $192 million to $196 million.
Why it matters — CYRX watchers would care because reaching positive adjusted EBITDA and reaffirming the full-year outlook signal continued progress in the company's core operations.
CryoPort, Inc. reported a Q2 loss of $0.2 per share, in line with the Zacks Consensus Estimate and narrower than the $0.29 per share loss from a year ago. The company beat revenue estimates, per the headline.
Why it matters — A CYRX watcher would note that the quarterly loss narrowed versus the prior year while revenue topped expectations, offering a factual read on the company's recent financial performance.
Cryoport announced its second quarter and first half 2026 financial results on August 6, 2026. Second quarter revenue grew 8% year-over-year to $49.0 million, with Life Sciences Services revenue up 15% and BioStorage/BioServices revenue up 25% year-over-year, while supporting 779 global clinical trials and 22 commercially approved cell and gene therapies as of June 30, 2026.
Why it matters — CYRX watchers would care because the quarter shows year-over-year revenue growth across its key service segments and an expanding base of supported clinical trials and approved cell and gene therapies.
The 9 Wall Street analysts covering CryoPort, Inc. have a median 12-month price target of $20, with estimates ranging from $15 to $25. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 9 analysts covering CryoPort, Inc., 8 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks CryoPort, Inc. 68 out of 100 across roughly 4,600 US stocks as at 15 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 15 Aug 2026, CryoPort, Inc. ranks 68 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (97 of 100).
No one can know that. What the data says: the median 12-month target from 9 analysts implies +31.1% from the last close, and Ticker Nerd's factor model ranks CryoPort, Inc. 68 out of 100 as at 15 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering CryoPort, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CYRX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $15 to $25 over the next 12 months.
CryoPort, Inc. returned +72.3% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Cryoport Inc. is a global provider specializing in temperature-controlled logistics solutions for the life sciences industry.
The most recent item we track (Zacks Investment Research, 11 Aug 2026): "CryoPort (CYRX) Upgraded to Buy: Here's Why". CryoPort (CYRX) was upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about its earnings prospects, according to Zacks Investment Research.
Cryoport Inc. is a global provider specializing in temperature-controlled logistics solutions for the life sciences industry. Its primary function is to ensure safe and efficient transportation of temperature-sensitive materials, including biological samples, pharmaceuticals, and other life sciences products. Notable for its comprehensive solutions, Cryoport offers a range of services including cryogenic transportation, monitoring, and logistics management, which are vital for maintaining product integrity and regulatory compliance. The company's offerings significantly impact sectors such as biotechnology, pharmaceuticals, and medical research, where precision and reliability are crucial. Cryoport's logistic services support the entire lifecycle of biopharmaceuticals, from research and development to clinical trials and commercialization. Cryoport's role in the financial market is underscored by its contribution to sustaining critical supply chains in the rapidly growing life sciences sector, making it a cornerstone for companies that rely on precise and secure logistics for their valuable materials. Headquartered in Nashville, Tennessee, Cryoport's innovation and commitment to quality make it a key player in enhancing the global capabilities of temperature-controlled logistic solutions for sensitive biological materials.
CEO Mr. Jerrell W. Shelton · 684 employees · United States · https://www.cryoportinc.com